Development and clinical application of peptide-based radiopharmaceuticals

Current Pharmaceutical Design

Volumn 10, Issue 24, 2004, Pages 2951-2963

  Gotthardt, M ^b   Boermann, O C ^a   Behr, T M ^b   Behe M P ^b   Oyen, W J G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Neuroendocrine; Radiopharmaceuticals; Receptor; Regulatory peptide; Scintigraphy; Somatostatin; Therapy; Tumor

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ANTIBODY; ARGINYLGLYCYLASPARTIC ACID; BISMUTH 213; BOMBESIN; CHELATING AGENT; COPPER 64; COPPER 67; DEPREOTIDE TC 99M; GALLIUM 67; GALLIUM 68; GASTRIN; GLUCAGON LIKE PEPTIDE 1; INDIUM 111; IODINE 123; IODINE 125; IODINE 131; NEUROTENSIN; OCTREOTIDE; PENTETIC ACID; PENTETREOTIDE; PEPTIDE; RADIOPHARMACEUTICAL AGENT; SAMARIUM 153; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; SUBSTANCE P; UNINDEXED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; YTTRIUM 90;

BINDING SITE; CHEMICAL MODIFICATION; CLINICAL TRIAL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG STRUCTURE; GENE OVEREXPRESSION; HUMAN; IMAGING; IN VIVO STUDY; INTERNALIZATION; ISOTOPE LABELING; LYSOSOME; MOLECULAR STABILITY; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROTEIN DEGRADATION; RADIOTHERAPY; RECEPTOR AFFINITY; REVIEW; SCINTIGRAPHY; TARGET CELL; TUMOR DIAGNOSIS;

CLINICAL TRIALS; DRUG DESIGN; FORECASTING; HUMANS; NEOPLASMS; PEPTIDE FRAGMENTS; RADIOPHARMACEUTICALS;

EID: 4544359900     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043383502     Document Type: Review

References (152)

1. Goldenberg DM, De Land F, Kim E, Bennett S, Primus FJ, van Nagell JR Jr, et al. Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N Engl J Med 1978; 298: 1384138-6
2. 131l-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphoma. Lancet 1993; 346: 336-340.
3. Behr TM, Memtsoudis S, Sharkey RM, Blumenthal RD, Dunn RM, Gratz S, et al. Experimental studies on the role of antibody fragments in cancer radioimmunotherapy: Influence of radiation dose and dose rate on toxicity and anti-tumor efficacy. Int. J. Cancer 1998, 77: 787-795.
4. Goldenberg DM, Goldenberg H, Sharkey RM, Lee RE, Higgenbotham-Ford E, Horowitz JA, et al. Imaging of colorectal carcinoma with radiolabeled antibodies. Semin Nucl Med 1989; 19: 262-281.
5. Reubi JC, Landolt AM. High density of somatostatin receptors in pituitary tumors from acromegalic patients. J Clin Endocrinol Metab. 1984; 59: 1148-1151.
6. Lamberts SW, Koper JW, Reubi JC. Potential role of somatostatin analogues in the treatment of cancer. Eur J Clin Invest 1987; 17: 281-287.
7. Lamberts SW, Bakker WH Reubi JC, Krenning EP. Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med 1990; 323: 1246-1249.
8. 111In-DTPA-D-PHE]-octreotide for detection of somatostatin receptor-positive tumors in rats. L Sci 1991; 49: 1593-1601.
9. 123I-Tyr3)-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20 (8): 716-731.
10. Reubi JC. Regulatory peptide receptors as molecular targets for cancer diagnosis and therapy. Q J Nucl Med 1997; 41: 63-70.
11. Behr TM, Gotthardt M, Barth A, Béhé M. Imaging tumors with peptide-based radioligands. Q J Nucl Med 2001; 45 (2): 189-200.
12. Modlin IM, Tang LH. Approaches to the diagnosis or gut neuroendocrine tumors: the last word today. Gastroenterology 1997; 112: 583-90.
13. Ricke J, Klose KJ. Imaging procedures in neuroendocrine tumors. Digestion 2000; 62 (suppl. 1): 39-44.
14. Ricke J, Klose KJ, Mignon, K Öbrg, B Wiedenmann. Standardisation of imaing in neuroendocrine tumours: results of a European Delphi process. Eur J Radiol 2001; 37: 8-17.
15. Termanini B, Gibril F, Reynolds JC, Doppman JL, Chen CC, Stewart CA, et al. Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management. Gastroenterology 1997: 112 (2): 335-47.
16. Lebtahi R, Cadiot G, Sarda L, Daou D, Faraggi M, Petegnief Y, et al. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med 1997; 38 (6): 853-8.
17. Gibril F, Reynolds JC, Chen CC, Yu F, Göbel SU, Serrano J, et al. Specificity of somatostatin receptor scintigraphy: a prospective study and effects or false-positive localizations on management in patients with gastrinomas. J Nucl Med 1999; 40 (4): 554-5.
18. Gotthardt M, Dirkmorfeld LM, Wied MU, Rinke A, Béhé MP, Schlieck A, et al. Influence of Somatostatin receptor scintigraphy and CT / MRI on the clinical management of patients with gastrointestinal neuroendocrine tumours: an analysis based on 188 patients. Digestion 2003; in press.
19. Weber WA, Haubner R, Vabuliene E, Kuhnast B, Wester HJ, Schwaiger M. Tumor angiogenesis targeting using imaging agents. Q J Nucl Med 2001; 45: 179-182.
20. 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer. Eur J Nucl Med Mol Imag 2003; 30: 1134-1139.
21. Gotthardt M, Fischer M, Holz JB, Jungclas H, Fritsch HW, Béhé M, et al. Use of the incretin hormon glucagon-like peptide-1 (GLP-1) for the detection of insulinomas: first experimental results. Eur J Nucl Med Mol Imag 2002; 29 (5): 597-60.
22. 3 integrin binding peptides in a nude mouse model. Cancer Res 2002; 62: 6146-6151.
23. Reubi JC. Neuropeptide receptors in health and disease: The molecular basis fo in vivo imaging. J Nucl Med 1995; 36: 1825-1835.
24. Behr TM, Gotthardt M, Becker W, Béhé M. Radioiodination of monoclonal antibodies, proteins, and peptides for diagnosis and therapy: a review of standardized, reliable and safe procedures for clinical grade levels kBq to GBq in the Göttingen / Marburg experience. Nuklearmedizin 2002; 41 (2): 71-79.
25. Meares CF, Moi MK, Diril H, Kukis DL, McCall MJ, Deshapnde SV, et al. Macrocyclic chelates of radiometals for diagnosis and therapy. Br J Cancer Suppl. 1990; 10: 21-26.
26. Heppeler A, Froidevaux S, Mäcke HR, Jermann E, Béhé M, Powell P, et al, Radiometal-Labelled Macrocyclic Chelator-Derivatised Somatostatin Analogue with Superb Tumour-Targeting Properties and Potential for Receptor-Mediated Internal Radiotherapy. Chem Europ J. 1999; 5: 1974-1981.
27. Stein R, Govindan SV, Mattes MJ, et al. Monoclonal antibodies labeled with radioiodinated, DTPA-appended peptides provide a significant therapeutic advantage for radioimmunotherapy. Eur J Nucl Med Mol Imag 2003; 30 (suppl): S199.
28. Stein R, Govindan SV, Mattes MJ, et al. Improved iodine radiolabels for monoclonal antibody therapy. Cancer Res 2003;63:111-8.
29. Jakubke HD. Peptide - Chemie und Biologie, Heidelberg: Spektrum Akademischer Verlag, 1996.
30. Jamar F, Fiasse R, Leners N, Pauwels S. Somatostatin receptor imaging with Indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy, and impact on patient management. J Nucl Med 1995; 36: 542-549.
31. Kwekkeboom DJ, Krenning E. Somatostatin receptor imaging. Sem Nucl Med 2002; 32 (2): 84-91.
32. Sreedharan SP, Kodama KT, Peterson KE, Goetzl EJ. Distinct subsets of somatostatin receptors on cultured human lymphocytes. J Biol Chem 1989; 264: 949-953.
33. Blum JE, Handmaker H, Rinne NA. The utility of a somatostatin-type receptor binding peptide radiopharamceutical (P829) in the evaluation of solitary pulmonary nodules. Chest 1999; 115: 224-232.
34. Stoffel M, Jamar F, Donckier J, Hainaut P, Decoster P, Beckers C, et al. Increased uptake of indium-111 pentetreotide up to 10 years after external thoracic irradiation: report of two cases. Eur J Nucl Med 1996; 23: 723-726.
35. Öberg K. Established clinical use of octreotide and lanreotide in oncology. Chemotherapy 2001; 47 (suppl 2): 40-53.
36. Krenning EP, Kwekkeboom DJ, Pauwels S, Kvols LK, Reubi JC. Somatostatin receptor scintigraphy. In: Freeman LM (ed.). Nuclear Medicine Annual 1995. New York: Raven Press, 1995, pp. 1-50.
37. Reubi JC, Lang W, Maurer R, Kooper JW, Lamberts SW. Distribution an biochemical characterization of somatostatin receptors in tumors of the central nervous system. Cancer Res 1987; 47: 5758-5765.
38. Reubi JC, Waser B, Foekens JA, Klijn JG, Lamberts SW, Laissue J. Somatostatin receptor incidence and distribution in breast cancer using receptor autoradiography: relationship to EGF-receptors. Int J Cancer 1990; 46: 416-420.
39. Reubi JC, Waser B, Sheppard M, Macauly V. Somatostatin receptors are present in small-cell but nor in non-small-cell primary lung carcinomas: relationship to EGF-receptors. Int J Cancer 1990; 45; 269-274
40. Reubi JC, Horisberger U, Waser B, Gebbers JO, Laissue J. Preferential location of somatostatin receptors in germinal centers of human gut lymphoid tissue. Gastroenterology 1992; 103: 1207-1214.
41. Reubi JC, Waser B, Van Hagen M, Lamberst SW, Krenning EP, Gebbers JO, et al. In vitro and in vivo detection of somatostatin receptors in human malignant lymphomas. Int J Cancer 1992; 50: 895-900.
42. Ur E, Mather SJ, Bomanji J, Ellison D, Britton KE, Grossman AB, et al. Pituitary imaging using a labelled somatostatin analog in acromegaly, Clin Endocrinol 1992; 36: 147-150.
43. 111Indium-pentetreotide pituitary scintigraphy and hormonal responses to octreotide in acromegalic patients. J Endocrinol Invest 1997; 20: 424-428.
44. Kwekkeboom DJ, de Herder WW, Krenning EP. Receptor imaging in the diagnosis and treatment of pituitary tumors. J Endocrinol Invest 1999; 22: 80-88.
45. De Bruin TWA, Kwekkeboom DJ, Van't Verlaat JW, Reubi JC, Krenning EP, Lamberts SW, et al. Clinically non-functioning pituitary adenoma and octreotide response to long-term high dose treatment, and studies in vitro. J Clin Endocrinol Metab 1992; 75: 1310-1317.
46. Merola B, Colao A, Ferone D, Selleri A, Di Sarno A, Marzullo P, et al. Effects of a chronic treatment with octreotide in patients with functionless pituitary adenomas. Horm Res 1992; 40: 149-155.
47. De Kerviler E, Cadiot G, Lebtahi R, Faraggi M, le Guludec D, Mignon M. Somatostatin receptor scintigraphy in 48 patients with the Zollinger-ellison Syndrome. Eur J Nucl Med 1994; 21: 1191-1197.
48. Gibril F, Reynolds JC, Doppman JL, Chen CC, Venzon DJ, Termanini BM, et al. Somatostatin receptor scintigraphy: its sensitivity compared to that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med 1996; 125: 26-34.
49. Zimmer T, Stölzel U, Bader M, Koppenhagen K, Hamm B, Buhr H, et al. Endoscopic ultrasonography and somatostatin receptor scintigraphy in the preoperative localization of insulinomas and gastrinomas. Gut 1996; 39: 562-568.
50. Kvols LK. Mediacl oncology considerations in patients with metastatic neuroendocrine carcinomas. Semin Oncol 1994; 21 (suppl 13): 56-60.
51. De Herder WW, Krenning EP, Malchoff CD, Hofland LJ, Reubi JC, Kwekkeboom DJ, et al. Somatostatin receptor scintigraphy: value in patients with the Cushing syndrome caused by ectopic corticotropin and / or CRH secretion. Am J Med 1994; 96: 305-312.
52. Philipponneau M, Nocaudie M, Epelbaum J, De Keyser Y, Lalau JD, Marchandise X, et al. Somatostatin analogs for the localization and preoperative treatment of an ACTH-secreting bronchial carcinoid tumor. J Clin Endocrinol Metab 1994; 78: 20-24.
53. Weiss M, Yellin A, Husza'r M, Eisenstein Z, Bar-Ziv J, Krausz Y. Localization of adrenocorticotropic hormone-secreting bronchial carcinoid tumor by somatostatin receptor scintigraphy. Ann Intern Med 1994; 121: 198-199.
54. Torpy DJ, Chen CC, Mullen N, Doppman JL, Carrasquillo JA, Chrousos GP, et al. Lack of utility of (111)In-pentetreotide scintigraphy in localizing ectopic ACTH-producing tumors: follow-up of 18 patients. J Clin Endocrinol Metab 1999; 84: 1186-1192.
55. Reubi JC, Waser B. Concomitant expression or several peptide receptors in neuroendocrine tumors: molecular basis for in vivo multireceptor imaging. Eur J Nucl Med Mol Imaging 2003; 30: 781-793.
56. Kwekkeboom DJ, Kho GS, Lamberts SW, Reubi JC, Laissue J, Krenning EP. The value of octeotide scintigraphy in patients with lung cancer. Eur J Nucl Med 1994; 21: 1106-1113.
57. Reisinger I, Bohuslavitzki KH, Brenner W, Braune S, Dittrich I, Geide A, et al. Somatostatin receptor scintigraphy in small cell lung cancer: results or a multicenter study. J Nucl Med 1998; 39: 224-227.
58. Reubi JC, Schaer JC, Laissue JA, Waser B. Somatostatin receptors and their subtypes in human tumors and in peritumoral vessels. Metab Clin Exp 1996; 45 (suppl 1): 39-41.
59. Behr TM, Gratz S, Markus PM, Dunn RM, Hüfner M, Schauer A. et al. Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors? Cancer 1997; 80: 2436-2457.
60. Kwekkeboom DJ, Reubi JC, Lamberts SW, Bruining HA, Mulder AH, Oei HY, et al. In vivo somatostatin receptor imaging in medullary thyroid carcinoma. J Clin Endocrinol Metab 1993; 76: 1413-1417.
61. Gotthardt M, Battmann A, Beuter D, Bauhofer A, Schipper ML, Béhé MP, et al. Comparison of In-111-D-Glu-1-Mingastrin, F-18-FDG PET, and CT scanning for the detection of metastatic medullary thyroid carcinoma. J Nucl Med 2003; 44 (5): 169P.
62. 18F-DOPA positron emission tomography for tumor detection in patients wilh medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med. 2001; 28 (1): 64-71.
63. Busnardo B, Girelli ME, Simioni N, Nacamulli D, Bosetto E. Nonparallel patterns of calcitonin and carcinoembryonic antigen levels in the follow-up of medullary thyroid carcinoma. Cancer 1984; 53: 278-285.
64. Haldemann AR, Rosler H, Barth A, Waser B, Geiger L, Godoy N, et al. Somatostatin receptor scintigraphy in central nervous system tumors: role a blood-brain barrier permeability. J Nucl Med 1995; 36: 403-410.
65. Schmidt M, Scheidhauer K, Luyken C, Voth E, Hildebrand G, Klug N, et al. Somatostatin receptor scintigraphy in intracranial tumors. Eur J Nucl Med 1998; 25: 675-686.
66. Reubi JC, Horisberger U, Lang W, Koper JW, Braakmann R, Lamberts SW. Coincidence of EGF receptors and somatostatin receptors in meningiomas but inverse, differentiation-dependent relationship in glial tumors. Am J Pathol 1989; 134: 337-344.
67. Gotthardt M, Henzel M, Béhé MP, Schlieck A, Schipper ML, Höffken H, et al. Influence of somatostatin receptor scintigraphy on therapeutic management and follow-up or patients with meningiomas. J Nucl Med 2003; 44 (5): 241P.
68. Van Hagen PM, Krenning EP, Reubi JC, Mulder AH, Bakker WH, Oei HY, et al. Somatostatin analogue scintigraphy of malignant lymphomas. Br J Haematol 1993; 83: 75-79.
69. Leners N, Jamar F, Fiasse R, Ferrant A, Pauwels S. Indium-111-pentetreotide uptake in neuroendocrine tumors and lympoma. J Nucl Med 1996; 37: 916-920.
70. Lugtenburg PJ, Lowenberg B, Valkema R, Oei HY, Lamberts SW, Eijkemans MJ, et al. Somatostatin receptor scintigraphy in the initial staging of low-grade non-Hodgkin's lymphomas. J Nucl Med 2001; 42: 222-229.
71. Lugtenburg PJ, Krenning EP, Valkema R, Oei HY, Lamberts SW, Eijkemans MJ, et al. Somatostatin receptor scintigraphy useful in stage I-II Hodgkin's disease: more extended disease identified. Br J Haematol 2001; 112: 936-944.
72. Van der Harst E, de Herder WW, Bruining HA, Bonjer HJ, de Krijger RR, Lamberts SW, et al. 1231-metaiodo benzylguanidine and 111In-octreotide uptake in benign and malignant phaeochromocytomas. J Clin Endocrinol Metab 2001; 86: 685-693.
73. Kwekkeboom DJ, Van Urk H, Pauw BK, Lamberts SW, Kooij PP, Hoog RP, et al. Octreotide scintigraphy for the detection of paraganlioma. J Nucl Med 1993; 34: 873-878.
74. Moertel CL, Reubi JC, Scheithauer BS, Schaid DJ, Kvols DK. Expression of somatostatin receptors in childhood neuroblastoma. Am J Clin Pathol 1994; 102: 752-756.
75. Postema PT, De Herder WW, Reubi JC, Oie HY, Kwekkeboom DJ, Bruining HJ et al. Somatostatin receptor scintgraphy in non-medullary thyroid cancer. Digestion 1996; 1: 36-37.
76. Stokkel MP, Reigmann HI, Verkooijen RB, Smit JW. Indium-111-octreotide scintigraphy in differentiated thyroid carcinoma metastases that do not respond to treatment with high-dose I-131. J Cancer Res Clin Oncol 2003; 129: 287-94.
77. Van Eijck CH, Krenning EP, Bootsma A, Oei HY, van Peel R, Lindemans J, et al. Somatostatin receptor scintigraphy in primary breast cancer. Lancet 1994; 343: 640-643.
78. Hoefnagel CA, Rankin EM, Valdés Olmos RA, Israels SP, Pavel S, et al. Sensitivity versus specificity in melanoma imaging using I-123 iodobenzamide and In-111 pentetreotide. Eur J Nucl Med 1994; 21: 587-588.
79. Kwekkeboom DJ, Hoff AM, Lamberts SW, Oei HY, Krenning EP. Somatostatin analog scintigraphy: a simple and sensitive method for the in vivo visualization of Merkel cell tumors and their metastases. Arch Dermatol 1992; 128: 818-821.
80. Kwekkeboom DJ, Krenning EP, Kho GS, Breemann WA, Van Hagen PM. Octreotide scintigraphy in patients with sarcoidosis. Eur J Nucl Med 1998; 25: 1284-1292.
81. Krassas GE, Dumas A, Pontikides N, Kaltsas T. Somatostatin receptor scintigraphy and octreotide teratment in patients with thyroid eye disease. Clin Endocrinol (Oxf) 1995; 42: 571-580.
82. Gerding MN, Van der Zant FM, van Royen EA, Koomneef L, Krenning EP, Wiersinga WM, et al. Octreotide scintigraphy is a disease-activity parameter in Grave's ophtalmopathy. Clin Endocrinol (Oxf) 1999; 50: 373-379.
83. 99mTc-depreotide. Sem Nucl Med 2002; 32: 92-96
84. Goldsmith S, Kostakoglu L. Role of nuclear medicine in the evaluation of the solitary pulmonary nodule. Semin Ultrasound CT MR 2000; 21: 129-138.
85. 99mTc-depreotide in the evaluation solitary pulmonary nodules. Chest 2000; 117: 1232-1238.
86. Grewal RK, Dadparvar S, Yu JQ, et al. Efficacy of 99mTc-depreotide scintigraphy in the evaluation of solitary pulmonary nodules. Cancer J 2002; 8: 400-404.
87. Ghambir SS, Shepard JE, Handmaker H, et al. Analysis of the cost-effectiveness of a somatostatin analog-99mTc-depreotide (Neotect) in the scintigraphic evaluation of solitary pulmonary nodules (SPN). J Nucl Med 1999. 40 (suppl): 57P.
88. Bangard M, Béhé M, Guhlke S, Otte R, Bender H, Maecke HR, et al. Detection of somatostatin receptor-positive tumors using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phel-octreotide. Eur J Nucl Med 2000; 27: 628-637.
89. Gabriel M, Decristoforo C, Donnemiller E, Ulmer H, Watfah Rychlinski C, Mather SJ, et al. An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors. J Nucl Med 2003; 44: 708-16.
90. 90Y-DOTA-Lanreotide: results an implications of the MAURITIUS trial. Sem Nucl Med 2002; 32: 148-155.
91. Reubi JC, Schär JC, Waser B. Affinity profiles for human somatostatin receptor subtypes sst1-sst5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med Mol Imag 2000; 27: 273-282.
92. Behr TM, Kann PH, Gotthardt M, Béhé M, Arnold R. Nuclear medicine diagnosis and therapy of neuroendocrine tumors of the gastrointestinal tract, including carcinoids. Der Nuklearmediziner 2003; 26: 121-133.
93. Behr TM, Jenner M, Béhé M, Angerstein C, Gratz S, Raue F, et al. Radiolabeled peptides for targeting of cholecystokinin-B/gastrin receptor expressing tumors: from preclinical development to initial clinical results. J Nucl Med 1999; 40: 1029-1044.
94. Behr TM, Jenner N, Radetzky S, Yücekent S, Raue F, Becker W. Targeting of cholecystokinin-B/gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabeled gastrin. Eur J Nucl Med. 1998; 25: 424-430.
95. Behr TM, Béhé M, Angerstein C, Gratz S, Mach R, Hagemann L, et al. Cholecystokinin-B/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential. Clin Cancer Res 1999; 5 (suppl. 10): 3124s-3138s.
96. Reubi JC, Waser B. Unexpected high incidence of cholecystokinin / gastrin receptors in human medullary thyroid carcinomas. Int J Cancer 1996; 67: 644-647.
97. Reubi JC, Schaer JC, Waser B. Cholecystokinin(CCK)-A and CCK-B / gastrin receptors in human tumors. Cancer Res 1997; 57: 1377-1386.
98. Gotthardt M, Grass J, Bh́é MP, Schipper ML, Schlieck A, Wied MU, et al. In-111-DTPA-DGlu-1-Minigastrin in the diagnosis of gastrointestinal neuroendocrine tumors: a comparison to In-111-pentetreotide. J Nucl Med 2003; 44 (5): 74P.
99. 1-Minigastrin for the determination of viability of malignant brain tumors: initial clinical results. Eur J Nucl Med 2002; 29 (suppl 1): S178.
100. Virgolini I, Kurtaran A, Raderer M, Leimer M, Angelberger P, Havlik E, et al. Vasoactive intestinal peptide receptor scintigraphy. J Nucl Med 1995; 36: 1732-1739.
101. Virgolini I, Raderer M, Kurtaran A, Angelberger P, Banyai S, Yang Q, et al. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N Engl J Med 1994; 331: 1116-1121.
102. 123I-vasoactive intestinal peptide (VIP) in the localization diagnosis of medullary thyroid carcinoma (MTC). Nucl Med Biol 1996; 23: 503-507.
103. Hessenius C, Bäder M, Meinhold H, Böhmig M, Faiss S, Reubi JC, et al. Vasoactive intestinal peptide receptor scintigraphy in patients with pancreatic adenocarcinomas or neuroendocrine tumors. Eur J Nucl Med 2000; 27: 1684-1693.
104. 99mTc labeled VIP analog: evaluation for imaging colorectal cancer. Nucl Med Biol 2001; 28: 445-450.
105. Thakur ML, Marcus CS, Saeed S, Pallela V, Minami C. Diggles L, et al. Imaging tumors in humans with Tc-99m-VIP. Ann N Y Acad Sci 2000; 921: 37-44.
106. Hennig IM, Laissue JA, Horisberger U, Reubi JC. Substance P receptors in human primary neoplasms. Int J Cancer 1995; 61: 786-792.
107. Van Hagen PM, Breeman WAP, Reubi JC, Postema PTE, van den Anker-Lugtenburg PJ, Kwekkeboom DJ, et al. Visualization of the thymus by substance P receptor scintigraphy in man. Eur J Nucl Med 1996; 23: 1508-1513.
108. Schumacher T, Hofer S, Good S, Reubi JC, Maecke H, Mueller-Brand J, et al. Diffusible Brachytherapie mit 90Y-Substanz P bei High Grade Gliomen: Erste Beobachtungen. In: Brink I, Högerle S, Moser E (Ed.): Nuklearmedizin als Paradigma molekularer Bildgebung, Blackwell, Berlin, Germany, 2002: 68.
109. van de Wiele C, Dumont F, Vanden Broecke R, Oosterlinck W, Cocquyt V, Serreyn R, et al. Technetium-99m RP 527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study. Eur J Nucl Med 2000; 27: 1694-1699.
110. Breeman WA, de Jong M, Erion JL, et al. Preclinical comparison of (111)In-labeled DTPA- or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy. J Nucl Med 2002; 43: 1650-6.
111. 99mTc demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging. Eur J Nucl Med Mol Imag 2003; 30: 247-258.
112. Ruoslahti E, Pierschbacher MD. New perspectives in cell adhesion: RGD and integrins. Science (Wash DC) 1987; 238: 491.497
113. Plow EF, Haas TA, Zhang L, Loftus J, Smith JW. Ligand binding to integrins. J Biol Chem 2000; 275: 21785-21788.
114. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994; 79: 1157-1164.
115. Haubner R, Wester HJ, Burkhart F, Senekowitsch-Schmidtke R, Weber W, Goodman SL, et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med 2001; 42: 326-336.
116. Van Hagen PM, Breeman WA, Bernard HF, Schaar M, Mooij CM, Srinivasan A, et al. Evaluation of a radiolablede cyclic DTPA-RGD analogur for tumor imaging and radionuclide therapy. Int J Cancer 2000; 90: 186-198.
117. 3 integrin antagonists: a new class of tracers for tumor targeting. J Nucl Med 1999; 40: 1061-1071.
118. 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 2001; 61: 1781-1785.
119. Lundqvist H, Tolmachev V. Targeting peptides and positron emission tomography. Biopolymers 2002; 66: 381-392.
120. Rogers BE, Bigott HM, McCarthy DW, Della Manna D, Kim J, Sharp TL, et al. Micro PET imaging of a gastrin-realising peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analog. Bioconjug Chem 2003; 14: 756-763.
121. Hofmann M, Maecke H, Borner R, Weckesser E, Schoffski P, Oei L, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Wur J Nucl Med 2001; 28: 1751-1757.
122. 3-Octreotide: First Results in Patients with Meningiomas. J Nucl Med 2001; 42: 1053-1056.
123. 86Y-DOTA(0)-d-phe(1)-Tyr(3)-octreotide (SMT 487) - a phase 1 clinical study: pharmakokiinetics, biodistribution, and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imag 2003; 30: 510-518.
124. Imam SK. Advancements in cancer therapy with alpha-emitters: a review. In J Radiat Oncol Biol Phys 2001; 51: 271-278.
125. de Jong M, Kwekkeboom DJ, R Valkema, Krenning EP. Radiolabelled peptides for tumour therapy: current status and future directions. Eur J Nucl Med Mol Imag 2003; 30: 463-469.
126. Chinol M, Bodei L, Cremonesi M, Paganelli G. Receptor-mediated radiotherapy with Y-DOTA-dPhe-Tyr-octreotide: the experience of the European institute of Oncology Group. Semin Nucl Med 2002; 32: 141-147.
127. 3-octreotide. Eur J Nucl Med 2001; 28: 426-434.
128. Paganelli G, Bodei L, Chinol M, Zoboli S, Cremonesi M, Gatti M, et al. Receptor-mediated radiotherapy with 90Y-DOTATOC: results of a phase 1 study. J Nucl Med 2001; 42: 36P.
129. Waldherr C, Pless M, Maecke HR, Haldemann H, Mueller-Brandt J. The clinical value of [90Y-DOTA]-d-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 2001; 12: 941-945.
130. Waldherr C, Pless M, Maecke HR, Schumacher T, Crazzolara A, Nitzsche EU, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq 90Y-DOTATOC. J Nucl Med 2002; 43: 610-616.
131. Waldherr C, Schumacher T, Maecke HR, Schirp U, Forrer F, Nitzsche EU, et al. Does tumor response depend on the number of treatment sessions at constatn injected doses using 90Y-DOTATOC in neuroendocrine tumours? Eur J Nucl Med 2002; 29: S100.
132. de Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WA, et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med 2002; 32: 133-140.
133. Smith MC, Liu J, Chen T, Schran H, Yeh CM, Jamar F, et al. OctreoTher: ongoing early clinical development of a somatostatin receptor-targeted antineoplastic therapy: Digestion 2000; 62 (suppl 1): 69-72.
134. Valkema R, Kvols LK, Jamar F, Bakker WH, Smith C, Krenning EP, et al. Phase I study of therapy with 90Y-SMT487 (OctreoTher) in patients with somatostatin receptor-positive tumors. J Nucl Med 2002; 43: 33P.
135. Jonard P, Jamar F, Walrand S, Collart JP, Valkema R, Bakker WH, et al. Tumor dosimetry based on PET86Y-DOTA-Tyr3-octreotide (SMT487) and CT-scan predicts tumor response to 90Y-SMT487 (OctreoTher). J Nucl Med 2000; 41: 111P.
136. Behr TM, Béhé M, Kluge G, Gotthardt M, Schipper ML, Gratz S, et al. Nephrotoxicity versus anti-tumor efficacy in radiopeptide therapy: facts and myths about the Scilla and Charybdis. Eur J Nucl Med Mol Imag 2002; 29 (2): 277.
137. Boerman OC, Oyen WJG, Corstens FH. Between the Scylla and Charybdis of peptide radionuclide therapy: hitting the tumour and saving the kidney. Eur J Nucl Med 2001; 28: 1447-1449.
138. Rolleman EJ, Valkema R, de Jong M, Kooij PPM, Krenning EP. Safe and effective inhibition of renal uptake of radiolabeled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imag 2003; 30: 9-15.
139. Béhé M, Kluge G, Angerstein C, Becker W, Behr TM. Kidney protection agents during radiopeptide therapy in mice. Eur J Nucl Med Mol Imag 2002; 29 (suppl 1): S301.
140. Rougier P, Mitry E. Chemotherapy in the treatment of neuroendocrine malignant tumors. Digestion 2000; 62 (suppl 1): 73-78.
141. Valkema R, de Jong M, Bakker WH, Breeman WA, Kooij PP, Lugtenburg PJ, et al. Phase 1 study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med 2002; 32: 110-122.
142. 111In pentetreotide. State of the art and perspectives. Q J Nucl Med 2000; 44: 88-95.
143. Anthony LB, Woltering EA, Espenan GD, Cronin MD, Maloney TJ, Mc Carthy KE. Indium-111-pentetreotide prolongs survival in gastroenteropancretic malignancies. Semin Nucl Med 2002; 32: 123-132.
144. Schipper ML, Gotthardt M, Béhé MP, Arnold R, Behr TM. Therapeutic efficacy and toxicity of In-111-DTPA-D-Phe-octreotide in patients with advanced neuroendocrine tumors. J Nucl Med 2003; 44 (5): 137P.
145. Kwekkeboom DJ, Bakker WH, Kam BL, Teunissen JJ, Kooij PP, De Herder WW, et al. Treatment of patients with gastroeneropancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0, Tyr3]octreotate. eur J nucl Med Mol Imag 2003; 30: 417-422.
146. Gotthardt M, Béhé MP, Schipper ML, Schlieck A, Höffken H, Behr TM. In-111-DTPA-D-Glu-1-Mingastrin used for therapy of metastatic medullary thyroid carcinoma and other neuroendocrine tumors: results of an ongoing dose-escalation study. J Nucl Med 2003; 44 (5): 137P.
147. de jong M, Breeman WA, Bernard HF, Bakker WH, van Gameren A, Bugaj JE, et al. Receptor-targeted radionuclide therapy using radiolabelled somatostatin analogs: tumour size versus curability. Eur J Nucl Med 2001; 28: 1026 P.
148. de Jong M, Bernard HF, Breeman WA, van Gameren A, Krenning EP. Combination of 90Y- or 177Lu-labeled somatostatin analogs is superior for radionuclide therapy compared to 90Y- or 177Lu-analogs alone. J Nucl Med 2002; 43: 123P-124P.
149. Reubi JC, Eisenwiener KP, Rink H, Waser B, Maecke HR. A new peptidic somatostatin agonist with high affinity to all somatostatin receptors. Eur J Pharmakol 2002; 456: 45-49.
150. Blum J, Handmaker H, Rinne NA. Technetium labeled small peptide radiopharmaceuticals in the identification of lung cancer. Curr Pharm Design 2002; 8(20): 1827-36.
151. Moody TW, Chan D, Fahrenkrug J, Jensen RT. Neuropeptides as autocrine growth factors in cancer cells. Curr Pharm Design 2003; 9(6): 495-509.
152. Vries EF, Buursma AR, Hospers GA, Mulder NH, Vaalburg W. Scintigraphic imaging of HSVtk gene therapy. Curr Pharm Design 2002; 8(16): 1435-50.